Radium-223 dichloride in prostate cancer: Major added benefit for certain patients
Thursday, April 3, 2014 - 11:12
in Health & Medicine
Radium-223 dichloride has been approved since November 2013 for men with advanced prostate cancer, in whom hormone blockade is no longer effective, and symptomatic bone metastases, but without visceral metastases. In an early benefit assessment, researchers examined whether this new drug offers an added benefit over the appropriate comparator therapy. No evaluable data were available for the comparison with docetaxel in patients in whom prolongation of life was the primary treatment goal. Hence an added benefit is not proven for this comparison.